COMPASS Pathways plc (NASDAQ:CMPS)
| Market Cap | 1.51B+70.6% |
| Revenue (ttm) | 0 |
| Net Income | -394.19M-185.4% |
| EPS | -5.57-202.7% |
| Shares Out | 134.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,184,920.395 |
| Open | 11.63 |
| Previous Close | 11.69 |
| Day's Range | 11.13 - 11.78 |
| 52-Week Range | 4.88 - 15.87 |
| Beta | 2.56 |
| Analysts | Buy |
| Price Target | 18.63(+66.64%) |
| Earnings Date | Nov 3, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About CMPS
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
$CMPS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CMPS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CMPS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CMPS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CMPS Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Single Operating Segment | $52.37M | 95.30% |
| Benefit from R&D tax credit | $2.58M | 4.70% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CMPS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CMPS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CMPS
| ETF | Est. Holding Size |
|---|---|
| ARKGARK Genomic Revolution ETF | $54.58M |
| IBBiShares Biotechnology ETF | $10.05M |
| PSILAdvisorShares Psychedelics ETF | $5.51M |
| SBIOALPS Medical Breakthroughs ETF | $2.06M |
| GWXState Street SPDR S&P International Small Cap ETF | $1.13M |
| SURISimplify Propel Opportunities ETF | $1.06M |
Estimated from each fund’s disclosed top holdings × AUM
CMPS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CMPS’s recent data — informational, not investment advice